<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581785</url>
  </required_header>
  <id_info>
    <org_study_id>LB001-001</org_study_id>
    <nct_id>NCT04581785</nct_id>
  </id_info>
  <brief_title>Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia</brief_title>
  <acronym>SUNRISE</acronym>
  <official_title>A Phase 1/2 Open-label Clinical Study of hLB-001 Gene Therapy in Pediatric Patients With Methylmalonic Acidemia Characterized by MMUT Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LogicBio Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LogicBio Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SUNRISE trial is a first-in-human (FIH), open-label, Phase 1/2 clinical trial designed to&#xD;
      assess the safety, tolerability and preliminary efficacy of a single intravenous infusion of&#xD;
      hLB-001 in pediatric patients with MMA characterized by methylmalonyl-CoA mutase gene (MMUT)&#xD;
      mutations. hLB-001 is a liver-targeted, recombinant engineered adeno-associated viral (rAAV)&#xD;
      vector utilizing the LK03 capsid (rAAV-LK03), designed to non-disruptively integrate the&#xD;
      human methylmalonyl-CoA mutase gene at the albumin locus.&#xD;
&#xD;
      The trial is expected to enroll pediatric patients with ages ranging from 6 months to 12&#xD;
      years, initially starting with 3 to 12 year-old patients and then adding patients aged 6&#xD;
      months to 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (AEs)</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of infusional toxicities</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum methylmalonic acid and methylcitrate</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum fibroblast growth factor 21 (FGF21) level</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in propionate oxidation rate</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum albumin-2A level</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: deaths of patients occurring during the study period will be collected</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Methylmalonic Acidemia</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 year-olds to12 year-olds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 month to 2 year-olds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 year-olds to12 year-olds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 month to 2 year-olds</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hLB-001</intervention_name>
    <description>hLB-001 via IV infusion</description>
    <arm_group_label>Dose Level 1 Part A</arm_group_label>
    <arm_group_label>Dose Level 1 Part B</arm_group_label>
    <arm_group_label>Dose Level 2 Part A</arm_group_label>
    <arm_group_label>Dose Level 2 Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At the time of dosing, patient must be 6 months to 12 years of age&#xD;
&#xD;
          -  Males and females with diagnosis of severe MMA meeting all the following;&#xD;
&#xD;
               1. Isolated MMA with genetically confirmed, pathogenic mutations in the MMUT gene&#xD;
&#xD;
               2. Screening serum/plasma methylmalonic acid level of &gt;100 Âµmol/L&#xD;
&#xD;
               3. One or more of the following considered by the PI to be MMA-related: (i) An&#xD;
                  unscheduled ER visit, hospitalization or requirement for sick day diet in the&#xD;
                  year prior to screening visit (ii) Developmental delay, movement disorder, optic&#xD;
                  neuropathy or feeding disorder with tube feeding requirement&#xD;
&#xD;
               4. Medically stable for the 2 months prior to the start of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with organic acidemias other than isolated MMA, or with any other causes of&#xD;
             hyperammonemia&#xD;
&#xD;
          -  Having received MMA-targeted gene therapy or nucleic acid therapy&#xD;
&#xD;
          -  Patients on insulin or high dose hydroxocobalamin (&gt; 1 mg/day OHB12 parenteral)&#xD;
&#xD;
          -  Kidney or liver transplant, including hepatocyte cell therapy&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) of &lt; 60 mL/min/1.73 m2 based on age&#xD;
             appropriate equations, or ongoing dialysis for renal disease&#xD;
&#xD;
          -  Patient tests positive for anti-rAAV-LK03-neutralizing antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Gruskin, MD</last_name>
    <role>Study Director</role>
    <affiliation>LogicBio Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>(617) 758-8059</phone>
    <email>clinicaltrials@logicbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Children's Health - Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hershonna S Robinson</last_name>
      <phone>650-497-0454</phone>
      <email>hsrobin@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andi Martinsen</last_name>
      <phone>720-777-4691</phone>
      <email>Andrea.Martinsen@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor Botha</last_name>
      <phone>404-778-8517</phone>
      <email>Egeller@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Tumblin</last_name>
      <phone>412-692-5969</phone>
      <email>mark.tumblin2@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Coman</last_name>
      <phone>615-875-9700</phone>
      <email>Diana.L.Coman@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Morgan</last_name>
      <phone>615-322-7601</phone>
      <email>thomas.m.morgan@vumc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayden Vreugdenhil</last_name>
      <phone>206-884-1264</phone>
      <email>Hayden.Vreugdenhil@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdullah Specialist Children Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Majid Alfadhel, MD</last_name>
      <phone>+966-011-801-1111</phone>
      <phone_ext>53560</phone_ext>
      <email>Fadhelma@ngha.med.sa</email>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.sunrisemma.com</url>
    <description>SUNRISE clinical trial website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>mut0</keyword>
  <keyword>mut-</keyword>
  <keyword>mut deficiency</keyword>
  <keyword>organic acidemia</keyword>
  <keyword>SUNRISE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

